MANKIND

Mankind Pharma Limited

Branded generics plus India's largest-selling consumer healthcare brands

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

mankindpharma.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹2275.50
Market cap
93,978 Cr
Stock P/E
45.9
P/B
5.76
Dividend yield
0.0%
ROE (FY26)
11.6%
ROCE (FY26)
13.0%
Operating margin (FY26)
19.1%
Debt / equity (FY26)
0.39
OCF / EBITDA (FY26)
86.3%
OCF / EBITDA (3Y)
83.8%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Mankind Pharma makes and sells branded generic medicines and consumer healthcare products, mainly to doctors and shoppers in India, with a smaller export business.

Company snapshot

9thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales2,708 Cr2,607 Cr2,441 Cr2,893 Cr3,077 Cr3,230 Cr3,079 Cr3,570 Cr3,697 Cr3,567 Cr3,443 Cr4,031 Cr
Operating expenses (approx.)2,025 Cr2,000 Cr1,850 Cr2,212 Cr2,226 Cr2,400 Cr2,396 Cr2,724 Cr2,776 Cr2,648 Cr2,513 Cr2,974 Cr
EBITDA683 Cr607 Cr591 Cr682 Cr850 Cr830 Cr683 Cr847 Cr921 Cr919 Cr930 Cr1,056 Cr
OPM %25.2%23.3%24.2%23.6%27.6%25.7%22.2%23.7%24.9%25.8%27.0%26.2%
Other income60 Cr70 Cr92 Cr101 Cr109 Cr77 Cr251 Cr80 Cr92 Cr73 Cr114 Cr45 Cr
Interest9 Cr9 Cr9 Cr11 Cr7 Cr221 Cr191 Cr171 Cr170 Cr157 Cr142 Cr110 Cr
Depreciation96 Cr110 Cr105 Cr108 Cr106 Cr192 Cr231 Cr219 Cr222 Cr223 Cr223 Cr226 Cr
Profit before tax641 Cr562 Cr572 Cr668 Cr849 Cr497 Cr511 Cr540 Cr624 Cr509 Cr659 Cr769 Cr
Tax %20.3%18.2%16.6%18.7%22.4%22.7%16.8%17.7%16.6%18.7%15.1%25.4%
Net profit511 Cr460 Cr477 Cr543 Cr659 Cr385 Cr425 Cr445 Cr520 Cr414 Cr559 Cr574 Cr
EPS (₹)₹12.51₹11.33₹11.76₹13.39₹16.31₹9.45₹10.19₹10.62₹12.39₹9.90₹13.44₹13.76

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5,865 Cr6,214 Cr7,782 Cr8,749 Cr10,335 Cr12,207 Cr14,278 CrSign in free for the trailing twelve months
Operating expenses (approx.)4,428 Cr4,566 Cr5,792 Cr6,849 Cr7,800 Cr9,190 Cr10,660 CrSign in free for the trailing twelve months
EBITDA1,437 Cr1,648 Cr1,989 Cr1,901 Cr2,535 Cr3,018 Cr3,617 CrSign in free for the trailing twelve months
OPM %24.5%26.5%25.6%21.7%24.5%24.7%25.3%Sign in free for the trailing twelve months
Other income110 Cr171 Cr196 Cr129 Cr281 Cr537 Cr359 CrSign in free for the trailing twelve months
Interest22 Cr20 Cr59 Cr44 Cr34 Cr429 Cr639 CrSign in free for the trailing twelve months
Depreciation99 Cr119 Cr167 Cr326 Cr398 Cr621 Cr886 CrSign in free for the trailing twelve months
Profit before tax1,438 Cr1,692 Cr1,975 Cr1,671 Cr2,399 Cr2,525 Cr2,333 CrSign in free for the trailing twelve months
Tax %26.5%23.6%26.4%21.6%19.1%20.3%16.9%Sign in free for the trailing twelve months
Net profit1,056 Cr1,293 Cr1,453 Cr1,310 Cr1,942 Cr2,011 Cr1,938 CrSign in free for the trailing twelve months
EPS (₹)₹25.72₹31.59₹35.78₹32.00₹47.75₹49.28₹46.35Sign in free for the trailing twelve months
Dividend payout %———0.0%0.0%0.0%2.1%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital40 Cr40 Cr40 Cr40 Cr40 Cr41 Cr41 Cr
Reserves3,445 Cr4,682 Cr6,115 Cr7,395 Cr9,323 Cr14,291 Cr16,259 Cr
Borrowings127 Cr235 Cr868 Cr170 Cr207 Cr8,511 Cr6,312 Cr
Other liabilities1,275 Cr1,275 Cr1,963 Cr1,922 Cr2,180 Cr4,680 Cr5,207 Cr
Total liabilities5,073 Cr6,373 Cr9,148 Cr9,715 Cr11,963 Cr27,760 Cr28,080 Cr
Fixed assets (net)1,499 Cr1,566 Cr1,652 Cr2,524 Cr2,932 Cr2,908 Cr2,960 Cr
CWIP313 Cr372 Cr670 Cr493 Cr207 Cr306 Cr655 Cr
Investments829 Cr1,512 Cr1,109 Cr1,352 Cr2,573 Cr2,042 Cr1,985 Cr
Loans & advances———2 Cr3 Cr4 Cr4 Cr
Inventories899 Cr1,184 Cr1,760 Cr1,498 Cr1,553 Cr2,094 Cr2,144 Cr
Trade receivables531 Cr331 Cr388 Cr576 Cr848 Cr1,538 Cr1,730 Cr
Cash & bank226 Cr167 Cr303 Cr305 Cr382 Cr407 Cr392 Cr
Other assets775 Cr1,242 Cr3,265 Cr2,965 Cr3,465 Cr18,460 Cr18,210 Cr
Total assets5,073 Cr6,373 Cr9,148 Cr9,715 Cr11,963 Cr27,760 Cr28,080 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity1,070 Cr1,137 Cr920 Cr1,813 Cr2,152 Cr2,413 Cr3,121 Cr
Cash from investing-439 Cr-1,222 Cr-1,369 Cr-1,054 Cr-2,082 Cr-12,683 Cr-196 Cr
Cash from financing-531 Cr-8 Cr605 Cr-740 Cr5 Cr10,290 Cr-2,953 Cr
Net cash flow100 Cr-93 Cr155 Cr22 Cr77 Cr22 Cr-12 Cr
Free cash flow (OCF − Capex)853 Cr826 Cr-1,423 Cr981 Cr1,770 Cr1,893 Cr2,384 Cr

Ratios

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %38.4%33.6%28.3%22.0%24.9%12.8%13.0%
ROE %28.1%26.0%22.7%16.8%20.0%13.6%11.6%
Debtor days33191824304644
Inventory days253314311301306378341
Days payable210177190202217205213
Cash conversion cycle76156139122119219172
OCF / EBITDA %74.4%69.0%46.2%95.4%84.9%80.0%86.3%
OCF / EBITDA % (3 years)——61.6%69.9%76.0%85.6%83.8%
Debt / equity0.040.050.140.020.020.590.39
Current ratio2.242.891.682.383.141.271.10
Net debt / EBITDA-0.070.040.28-0.07-0.072.691.64